



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Felix Kratz	Attorney Docket:	25048/20
Serial No.:	10/009,854	Examiner:	Jeffrey F. Russel
Filing Date:	Dec 11, 2001	Group Art Unit:	1645
Title:	CARRIER-DRUG CONJUGATE	Confirmation No.:	6344
		Customer No.:	000046591

APPLICANT'S ATTORNEY INTERVIEW SUMMARY RECORD

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

A telephonic interview as held on February 22, 2007. Examiner Jeffrey F. Russel and J. Herbert O'Toole were the participants.

No exhibits were shown.

The status of the claims- which set had been entered and which set excluded- was discussed. No art was cited and no claims content was discussed. Specifically, the claims of record are those filed October 23, 2006.


No later claims are of record.

The amendments to the specification submitted October 23, 2006 and January 23, 2007 were not entered.

The Examiner insisted that SEQ ID No.'s must be shown on the Figs. Or in the Description of the Figs., even when the amino acid sequence is not novel and is inserted into a non-peptide sequence.

The issues were clarified. No specific agreement was reached.

Respectfully submitted,



Herbert O'Toole
Registration No. 31,404
Attorney for Patentee
NEXSEN PRUET, LLC
P.O. Box 10107
Greenville, SC 29603
Telephone: 864/ 370- 2211
Facsimile: 864/ 282-1177

I hereby **CERTIFY** that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope address to: Commissioner
for Patents, P.O. Box 1450, Alexandria VA 22313-1450

Date: June 11 2007

by: Jacqueline Beavers

